|
 Home
|
|
Back
|
Magnetic nanoparticles show prostate cancer bone-sparing promise
|
MedWire News: Tumor proliferation in the bone, as well as bone destruction, is suppressed in prostate cancer patients with magnetite nanoparticles conjugated with cationic liposomes (MCLs) plus alternating magnetic field (AMF) exposure, Japanese study findings suggest.
Having developed MCLs for the induction of intracellular hyperthermia on exposure to AMF, Noriyasu Kawai, from Nagoya City University Graduate School of Medical Sciences, and colleagues previously demonstrated the effect of MCLs against malignant tumor cells in vivo.
To examine the effect of MCL+AMF heat therapy on prostate cancer in a bone microenvironment and on bone destruction, the team transplanted rat prostate cancer nodules onto the calvaria of 6-week-old F344 male rats. Tumors 7 mm in diameter were injected with MCLs, and the animals were then exposed to repeated AMF irradiation.
The findings, published in The Prostate, reveal that tumor growth on the calvaria was suppressed by MCL+AMF, and, histologically, the induction of a necrotic mass was observed around the magnetic particles.
In comparison with controls, rats injected with MCLs had a significantly lower bone-destruction index, indicating the degree of osteolysis associated with prostate tumor growth in the bone microenvironment, at 34.8% versus 67.2%. However, the team points out that almost half the animals died.
They say: "In conclusion, local MCL+AMF heat therapy induced necrosis in prostate cancer and suppressed osteolysis in the bone microenvironment, however this method may exhibit side effects for central nerve system."
"Further study is necessary to establish an appropriate MCL injection for MCL+AMF heat therapy in the clinical setting to let MCL specifically taken into the prostate tumor cells in the bone microenvironment."
The Prostate 2008; 68: 784-792
http://www3.interscience.wiley.com/journal/117923100/abstract
|
|
|
Search
Information for
This is an AstraZeneca International website for healthcare professionals. The site is not intended for the following audiences who should use the links below:
Zoladex news feed
Please note
Not all indications / uses of ZOLADEX are registered in all countries. Please consult local prescribing information.
Quick links
Features
Site services
|
|
| |
|
|
